Entyvio ® (Vedolizumab)
AI Summary
UnitedHealthCare has revised their medical benefit drug policy for Entyvio (vedolizumab), a specialty medication used to treat inflammatory bowel diseases like Crohn's disease and ulcerative colitis. The updated policy changes coverage criteria, prior authorization requirements, or administration guidelines for this high-cost infusion therapy.
Action Required
Before August 1, 2026: Billing team must review the revised Entyvio policy at uhcprovider.com to understand updated coverage criteria and prior authorization requirements. Update billing workflows for vedolizumab claims and notify gastroenterology providers of any new documentation requirements. Failure to comply with revised policy may result in claim denials for this high-cost specialty drug.
Plan Types
Commercial
Specialties
gastroenterology